Eli Lilly has confirmed plans for a $1.3 billion takeover bid for Verve Therapeutics, upgrading a collaboration between the ...

Factor XIIa inhibitor Andembry (garadacimab) has been cleared in the US for use in patients aged 12 and over with HAE, which ...

The IPO comes just a few weeks after Caris raised $168 million in a private financing round that took the total raised by the ...

In April, Verve tweaked the development of the first PCSK9 inhibitor in its programme (VERVE-101) after a trial revealed ...

Other appointments to BIO's board for the 2025 through 2026 term include: Arcutis Bio's Frank Watanabe, named vice-chair; ...

Dr Lindborg shares her journey to her present role, the true potential shown in this new data for addressing unmet needs in ...

That challenge, of finding or building good, useable data sets, is also one of the biggest differentiators in an increasingly ...

The terms include an upfront payment of $8.50 per share for Sage, giving Supernus rights to its FDA-approved post-partum ...

The annual conference of the Biotechnology Innovation Organization (BIO) is always an anticipated gathering where pharma and ...

The Inflation Reduction Act (IRA), signed into law in August 2022, marked a historic shift in US healthcare policy by ...

Jeremy Skillington, CEO of LSE-listed Poolbeg Pharma, which has programmes targeting areas of high unmet medical need, ...

Johnson & Johnson has new data showing that combining two of its multiple myeloma therapies – Talvey and Tecvayli – has been ...